Stopping a GLP-1 receptor agonist or tirzepatide isn't a neutral event — emerging evidence suggests it may set off a cascade of cardiometabolic consequences that could partially negate the benefits these drugs delivered while in use. For the tens of millions now prescribed these medications, understanding discontinuation risk is arguably as important as understanding the drugs themselves.

A review published in Nature Reviews Endocrinology examines real-world persistence data on GLP-1 receptor agonists (such as semaglutide and liraglutide) and tirzepatide — a dual GLP-1/GIP receptor agonist — finding that a substantial proportion of patients discontinue within the first year of therapy. Primary drivers include gastrointestinal side effects, insufficient perceived efficacy, out-of-pocket cost burdens, and concern over rare adverse events. Upon stopping, patients commonly experience weight regain alongside deterioration of glycemic control, blood pressure, lipid profiles, and other cardiometabolic markers. The review raises particular concern about cyclical initiation-interruption-reinitiation patterns, which may produce oscillations in HbA1c and body weight — themselves independent risk factors for cardiovascular and microvascular disease. Crucially, the authors flag the absence of anti-atherosclerotic and plaque-stabilizing effects during off-treatment periods as a potential acute cardiovascular vulnerability window.

This analysis lands at a critical inflection point in GLP-1 pharmacology. While landmark trials like SUSTAIN-6, LEADER, and SURPASS-CVOT established robust on-treatment cardiometabolic benefits, the off-treatment trajectory has received far less rigorous investigation. The "weight cycling" hypothesis — that repeated gain-loss cycles may independently worsen metabolic and vascular outcomes — has prior observational support, but how it interacts specifically with incretin-based therapy remains poorly characterized. The review's emphasis on plaque vulnerability during acute discontinuation echoes concerns from statin-withdrawal literature, where abrupt cessation has been linked to rebound inflammatory activity. Key limitations acknowledged include sparse prospective discontinuation data, reliance on observational real-world claims datasets, and heterogeneous patient populations. For health-conscious adults and clinicians alike, this analysis repositions adherence support — not just drug selection — as a central pillar of long-term cardiometabolic management.